High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies

Thoracic Cancer

Volumn 7, Issue 1, 2016, Pages 100-110

  Fu, Shuai ^a   Zhao, Jun ^a   Bai, Hua ^a   Duan, Jianchun ^a   Wang, Zhijie ^a   An, Tongtong ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Bronchoscopy; Genotype; NSCLC; Patient derived xenograft model

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; SCATTER FACTOR RECEPTOR;

ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSCOPY; C MET GENE; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NOD SCID MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTO ONCOGENE; ROS PROTO ONCOGENE 1; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; TUMOR XENOGRAFT;

EID: 84956678558     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12291     Document Type: Article

References (39)

1. Paez JG, Jänne PA, Lee JC etal. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
2. Lynch TJ, Bell DW, Sordella R etal. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
3. Pao W, Miller V, Zakowski M etal. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
4. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
5. Mitsudomi T, Morita S, Yatabe Y etal. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
6. Zhou C, Wu YL, Chen G etal. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
7. Rosell R, Carcereny E, Gervais R etal. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
8. Stacey SN, Sulem P, Jonasdottir A etal. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011; 43: 1098-1103.
9. Xiong D, Li G, Li K etal. Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. Carcinogenesis 2012; 33: 1797-1805.
10. Liu P, Morrison C, Wang L etal. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012; 33: 1270-1276.
11. Ignatius Ou SH, Azada M, Hsiang DJ etal. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014; 9: 549-553.
12. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006; 6: 565-571.
13. Philip R, Carrington L, Chan M. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Bioanalysis 2011; 3: 383-389.
14. Daniel VC, Marchionni L, Hierman JS etal. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009; 69: 3364-3373.
15. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9: 4227-4239.
16. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: A pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 2009; 36: 454-459.
17. Bernardo C, Costa C, Amaro T etal. Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: An exploratory model study. Anticancer Res 2014; 34: 735-744.
18. Mattie M, Christensen A, Chang MS etal. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 2013; 15: 1138-1150.
19. Lin D, Wyatt AW, Xue H etal. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014; 74: 1272-1283.
20. Zhang XC, Zhang J, Li M etal. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies. J Transl Med 2013; 11: 168.
21. Han X, Zhang Z, Wu D etal. Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on Chinese population. Transl Oncol 2014; 7: 795-799.
22. Lee Y, Lee GK, Hwang JA, Yun T, Kim HT, Lee JS. Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. Clin Lung Cancer 2015; 16: 46-50.
23. Zhao F, Xu M, Lei H etal. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A meta-analysis. PLoS ONE 2015; 10 (2): e0117333.
24. Kim Y, Hammerman PS, Kim J etal. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014; 32: 121-128.
25. Bai H, Mao L, Wang HS etal. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 2653-2659.
26. Bai H, Wang Z, Chen K etal. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012; 30: 3077-3083.
27. Wang S, An T, Wang J etal. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 1324-1330.
28. Fichtner I, Rolff J, Soong R etal. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-6468.
29. Merk J, Rolff J, Dorn C, Leschber G, Fichtner I. Chemoresistance in non-small-cell lung cancer: Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 2011; 40: e29-33.
30. John T, Kohler D, Pintilie M etal. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011; 17: 134-141.
31. Sorensen M, Pijls-Johannesma M, Felip E. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v120-125.
32. Rossi G, Cavazza A, Sturm N etal. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: A clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003; 27: 311-324.
33. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75: 191-202.
34. Ali G, Proietti A, Niccoli C etal. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. Lung Cancer 2013; 81: 297-301.
35. Kobayashi Y, Sakao Y, Ito S etal. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol 2013; 8: e75-78.
36. Weiss J, Sos ML, Seidel D etal. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
37. Kim HR, Kim DJ, Kang DR etal. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013; 31: 731-737.
38. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A etal. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014; 156: 1298-1311.
39. Nik-Zainal S, Van Loo P, Wedge DC etal. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.